DUBLIN, IRELAND--(Marketwire - May 21, 2008) - AGI Therapeutics plc ("AGI" or the "Company") (AIM, IEX: AGI), a speciality pharmaceutical company focused on gastrointestinal drug products, today announces the key pharmacology and clinical findings related to Rezular (arverapamil, AGI-003), which is being developed by the Company as a gastrointestinal-selective agent for the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D), recently presented at Digestive Disease Week (DDW) on Tuesday 20 May, 2008.
